Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

The CBFβ-SMMHC/NRP1 Axis Regulates FLT3 and TGF-Beta Pathways in Inv(16) Acute Myeloid Leukemia

Mahesh Hegde, Mohd Hafiz Ahmad, Rui Li, Anneliese Carrascoso, Roger Mulet-Lazaro, Ruud Delwel, John H. Bushweller, Monica L. Guzman, Scot A. Wolfe, Julie Zhu, Lucio H. Castilla

Blood (2021) 138 (Supplement 1): 3314.

https://doi.org/10.1182/blood-2021-153275

Published: 2021

Journal Articles

An erythroid-to-myeloid cell fate conversion is elicited by LSD1 inactivation

Lei Yu, Greggory Myers, Chia-Jui Ku, Emily Schneider, Yu Wang, Sharon A. Singh, Natee Jearawiriyapaisarn, Andrew White, Takashi Moriguchi, Rami Khoriaty, Masayuki Yamamoto, Michael G. Rosenfeld, Julien Pedron, John H. Bushweller, Kim-Chew Lim, James Douglas Engel

Blood (2021) 138 (18): 1691–1704.

https://doi.org/10.1182/blood.2021011682

Published: 2021

Includes: Supplemental data

Journal Articles

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

Blood (2019) 134 (1): 59–73.

https://doi.org/10.1182/blood.2018893982

Published: 2019

Includes: Supplemental data

Journal Articles

Direct Binding of BCOR, but Not CBX8, to MLL-AF9 Is Essential for MLL-AF9 Leukemia Via Regulation of the EYA1/SIX1 Gene Network

John H. Bushweller, PhD, Charles Schmidt, Nicholas Achille, Aravinda Kuntimaddi, Adam Boulton, Benjamin Leach, Shubin Zhang, Nancy J. Zeleznik-Le, PhD

Blood (2018) 132 (Supplement 1): 1316.

https://doi.org/10.1182/blood-2018-99-111388

Published: 2018

Journal Articles

CBFβ-SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv(16) Leukemia

John Anto Pulikkan, PhD, Mahesh Hegde, Houda Belaghzal, Anuradha Illendula, Jun Yu, Hafiz Ahmed, Kelsey O'Hagen, Jianhong Ou, Carsten Müller-Tidow, Scot A. Wolfe, Julie Zhu, Job Dekker, John H. Bushweller, Lucio H. Castilla

Blood (2017) 130 (Supplement 1): 784.

https://doi.org/10.1182/blood.V130.Suppl_1.784.784

Published: 2017

Journal Articles

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia

AHyun Choi, Anuradha Illendula, John A. Pulikkan, Justine E. Roderick, Jessica Tesell, Jun Yu, Nicole Hermance, Lihua Julie Zhu, Lucio H. Castilla, John H. Bushweller, Michelle A. Kelliher

Blood (2017) 130 (15): 1722–1733.

https://doi.org/10.1182/blood-2017-03-775536

Published: 2017

Includes: Supplemental data

Journal Articles

Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML

John Anto Pulikkan, PhD, Anuradha Illendula, PhD, Jolanta Grembecka, Liting Xue, Roger Rajewski, Monica L. Guzman, PhD, John H. Bushweller, PhD, Lucio H. Castilla, PhD

Blood (2014) 124 (21): 390.

https://doi.org/10.1182/blood.V124.21.390.390

Published: 2014

Journal Articles

Structural and Functional Studies Of The Intrinsically Disordered Protein AF9 In MLL-AF9 Leukemia

Aravinda Kuntimaddi, Alyson Lokken, Shubin Zhang, Jeremy Thorpe, Benjamin Leach, PhD, Bhavna Lumba, PhD, Charles S. Hemenway, MD, PhD, Mazhar Adli, PhD, Nancy J. Zeleznik-Le, PhD, John H. Bushweller, PhD

Blood (2013) 122 (21): 3762.

https://doi.org/10.1182/blood.V122.21.3762.3762

Published: 2013

Journal Articles

A Small Molecule Inhibitor of the CBFβ-SMMHC/RUNX Interaction Attenuates Inv(16) Leukemia in Vivo

John H. Bushweller, PhD, Anuradha Illendula, Ph.D., John Anto Pulikkan, Jolanta Grembecka, PhD, Paul Bradley, Yunpeng Zhou, Ph.D., Liting Xue, Yan Gao, Lucio H. Castilla, PhD

Blood (2012) 120 (21): 286.

https://doi.org/10.1182/blood.V120.21.286.286

Published: 2012

Journal Articles

The Role of the Intrinsically Disordered and Multifunctional AF9 C-Terminal Domain in MLL-AF9 Leukemia,

John H. Bushweller, PhD, Benjamin Leach, Ming-jin Chang, Bhavna Lumba, Tomasz Cierpicki, PhD, Nancy J. Zeleznik-Le, PhD, Charles S. Hemenway, MD, PhD

Blood (2011) 118 (21): 3464.

https://doi.org/10.1182/blood.V118.21.3464.3464

Published: 2011

Journal Articles

DNMT1 Cxxc Domain Can Functionally Substitute In An MLL Fusion Protein

Laurie E. Risner, PhD, Aravinda Kuntimaddi, John H. Bushweller, PhD, Nancy J. Zeleznik-Le, PhD

Blood (2010) 116 (21): 4193.

https://doi.org/10.1182/blood.V116.21.4193.4193

Published: 2010

Journal Articles

Structural Basis for MLL Cxxc Domain Protection against CpG DNA Methylation and the Essential Role of This Function in MLL-AF9 Leukemia.

Laurie Risner, Tomasz Cierpicki, PhD, Jolanta Grembecka, PhD, Stephen M Lukasik, PhD, Relja Popovic, PhD, David S Shultis, PhD, Nancy J. Zeleznik-Le, PhD, John H. Bushweller, PhD

Blood (2009) 114 (22): 763.

https://doi.org/10.1182/blood.V114.22.763.763

Published: 2009

Journal Articles

The role of CBFβ in AML1-ETO's activity

Sangho Park, Nancy A. Speck, John H. Bushweller

Blood (2009) 114 (13): 2849–2850.

https://doi.org/10.1182/blood-2009-07-231233

Published: 2009

Journal Articles

Structure of the AML1-ETO eTAFH domain–HEB peptide complex and its contribution to AML1-ETO activity

Sangho Park, Wei Chen, Tomasz Cierpicki, Marco Tonelli, Xiongwei Cai, Nancy A. Speck, John H. Bushweller

Blood (2009) 113 (15): 3558–3567.

https://doi.org/10.1182/blood-2008-06-161307

Published: 2009

Includes: Supplemental data

Journal Articles

CBFβ is critical for AML1-ETO and TEL-AML1 activity

Liya Roudaia, Matthew D. Cheney, Ekaterina Manuylova, Wei Chen, Michelle Morrow, Sangho Park, Chung-Tsai Lee, Prabhjot Kaur, Owen Williams, John H. Bushweller, Nancy A. Speck

Blood (2009) 113 (13): 3070–3079.

https://doi.org/10.1182/blood-2008-03-147207

Published: 2009

Journal Articles

Development of Small Molecule Inhibitors of the AML1-ETO and CBFβ-SMMHC Oncoproteins.

Jolanta E. Grembecka, PhD, Kristin Graf, Yali Kong, PhD, Michael Douvas, MD, Tomasz Cierpicki, PhD, Anuradha Illendula, PhD, Gwen Baber, Izabela Bielnicka, Liya Roudaia, Nancy A. Speck, PhD, Milton L. Brown, PhD, MD, John H. Bushweller, PhD

Blood (2007) 110 (11): 1591.

https://doi.org/10.1182/blood.V110.11.1591.1591

Published: 2007

Journal Articles

Structural and Functional Characterization of the NHR2 and Runt Domains of AML1/ETO.

Matthew D. Cheney, AB, Yizhou Liu, MS, Justin J. Gaudet, BS, Maksymilian Chruszcz, PhD, Stephen M. Lukasik, BS, Daisuke Sugiyama, MD, PhD, Jeff Lary, PhD, James Cole, PhD, Zbyszek Dauter, PhD, Wladek Minor, PhD, Nancy A. Speck, PhD, John H. Bushweller, PhD

Blood (2005) 106 (11): 2854.

https://doi.org/10.1182/blood.V106.11.2854.2854

Published: 2005

Journal Articles

The CBFb-SMMHC Oncoprotein Inhibits Binding of the Runx1 Runt Domain to DNA.

John H. Bushweller, PhD, Stephen M. Lukasik, BS, Nancy A. Speck, PhD

Blood (2005) 106 (11): 2709.

https://doi.org/10.1182/blood.V106.11.2709.2709

Published: 2005

Journal Articles

Development of Small Molecule Inhibitors of the CBFβ-SMMHC Oncoprotein.

John H. Bushweller, PhD, Michael J. Gorczynski, PhD, Jolanta Grembecka, PhD, Miki Newman, MS, Takeshi Corpora, BA, Yunpeng Zhou, BS, Yali Kong, PhD, Jae-Pil Jeon, PhD, Pu Paul Liu, PhD, Milton L. Brown, PhD

Blood (2005) 106 (11): 3359.

https://doi.org/10.1182/blood.V106.11.3359.3359

Published: 2005

Journal Articles

Development of Small Molecule Inhibitor of the AML1-ETO Oncoprotein.

Jolanta Grembecka, PhD, Kristin Graf, Miki Newman, Yunpeng Zhou, Mathew Cheney, Nancy A. Speck, PhD, Milton L. Brown, PhD, John H. Bushweller, PhD

Blood (2005) 106 (11): 1515.

https://doi.org/10.1182/blood.V106.11.1515.1515

Published: 2005

NARROW

The CBFβ-SMMHC/NRP1 Axis Regulates FLT3 and TGF-Beta Pathways in Inv(16) Acute Myeloid Leukemia

An erythroid-to-myeloid cell fate conversion is elicited by LSD1 inactivation

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

Direct Binding of BCOR, but Not CBX8, to MLL-AF9 Is Essential for MLL-AF9 Leukemia Via Regulation of the EYA1/SIX1 Gene Network

CBFβ-SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv(16) Leukemia

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia

Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML

Structural and Functional Studies Of The Intrinsically Disordered Protein AF9 In MLL-AF9 Leukemia

A Small Molecule Inhibitor of the CBFβ-SMMHC/RUNX Interaction Attenuates Inv(16) Leukemia in Vivo

The Role of the Intrinsically Disordered and Multifunctional AF9 C-Terminal Domain in MLL-AF9 Leukemia,

DNMT1 Cxxc Domain Can Functionally Substitute In An MLL Fusion Protein

Structural Basis for MLL Cxxc Domain Protection against CpG DNA Methylation and the Essential Role of This Function in MLL-AF9 Leukemia.

The role of CBFβ in AML1-ETO's activity

Structure of the AML1-ETO eTAFH domain–HEB peptide complex and its contribution to AML1-ETO activity

CBFβ is critical for AML1-ETO and TEL-AML1 activity

Development of Small Molecule Inhibitors of the AML1-ETO and CBFβ-SMMHC Oncoproteins.

Structural and Functional Characterization of the NHR2 and Runt Domains of AML1/ETO.

The CBFb-SMMHC Oncoprotein Inhibits Binding of the Runx1 Runt Domain to DNA.

Development of Small Molecule Inhibitors of the CBFβ-SMMHC Oncoprotein.

Development of Small Molecule Inhibitor of the AML1-ETO Oncoprotein.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only